Introduction & Objectives: The rate of non-interventional treatment (NIT) in prostate cancer (PCa) active surveillance (AS) candidates were shown to be on the rise. However, contemporary data have not been reported. To address this void, we examined NIT rate between 2010-2014, within 16 Surveillance Epidemiology and End Results (SEER) registries. Materials & Methods: We identified 21,398 PCa patients that fulfilled the University of California, San Francisco AS criteria (prostate specific antigen [PSA] \u3c10ng/ml, clinical T stage 4ng/ml, cT2a and \u3e1 positive core) only the proportion of NIT patients aged Conclusions: The rate of NIT as markedly increased across all examined SEER-registries. Nonetheless, very important differences disti...
Objective: Knowledge about factors influencing choice of and adherence to active surveillance (AS) f...
Purpose: Active surveillance to manage prostate cancer provides an alternative to immediate treatmen...
PURPOSE: To evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate ca...
Introduction & Objectives: The rate of non-interventional treatment (NIT) in prostate cancer (PCa) a...
BACKGROUND: The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillan...
We quantified the 2010-2014 rate of noninterventional treatment (NIT) management in active surveilla...
BACKGROUND: Active surveillance (AS) is increasingly recognized as a recommended treatment option fo...
Introduction & Objectives: The last decade witnessed an increasing adoption of active surveillance (...
In the last decade, active surveillance (AS) has emerged as an acceptable choice for low-risk prosta...
Background: Regional differences in active surveillance (AS) uptake for prostate cancer (PC) illustr...
BACKGROUND: This study assessed the use of active surveillance in men with low-risk prostate cancer ...
[EN] Introduction: Prostate cancer is the second most frequent cancer and the fifth leading...
Background: Men with prostate cancer on active surveillance (AS) are advised to follow strict follow...
BackgroundActive surveillance followed by selective treatment for men who have evidence of disease p...
Context: Prostate cancer (PCa) remains an increasingly common malignancy worldwide. The optimal mana...
Objective: Knowledge about factors influencing choice of and adherence to active surveillance (AS) f...
Purpose: Active surveillance to manage prostate cancer provides an alternative to immediate treatmen...
PURPOSE: To evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate ca...
Introduction & Objectives: The rate of non-interventional treatment (NIT) in prostate cancer (PCa) a...
BACKGROUND: The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillan...
We quantified the 2010-2014 rate of noninterventional treatment (NIT) management in active surveilla...
BACKGROUND: Active surveillance (AS) is increasingly recognized as a recommended treatment option fo...
Introduction & Objectives: The last decade witnessed an increasing adoption of active surveillance (...
In the last decade, active surveillance (AS) has emerged as an acceptable choice for low-risk prosta...
Background: Regional differences in active surveillance (AS) uptake for prostate cancer (PC) illustr...
BACKGROUND: This study assessed the use of active surveillance in men with low-risk prostate cancer ...
[EN] Introduction: Prostate cancer is the second most frequent cancer and the fifth leading...
Background: Men with prostate cancer on active surveillance (AS) are advised to follow strict follow...
BackgroundActive surveillance followed by selective treatment for men who have evidence of disease p...
Context: Prostate cancer (PCa) remains an increasingly common malignancy worldwide. The optimal mana...
Objective: Knowledge about factors influencing choice of and adherence to active surveillance (AS) f...
Purpose: Active surveillance to manage prostate cancer provides an alternative to immediate treatmen...
PURPOSE: To evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate ca...